Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells

Diabetologia

Volumn 41, Issue 12, 1998, Pages 1435-1441

  Yamagishi, S ^a   Fujimori, H ^a   Yonekura, H ^a   Yamamoto, Y ^a   Yamamoto, H ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Advanced glycation endproducts; Endothelial cells; Microangiopathy; Plasminogen activator inhibitor 1; Thrombogenesis

Indexed keywords

CYCLIC AMP; FIBRIN; FORSKOLIN; PLASMINOGEN ACTIVATOR INHIBITOR; PROSTACYCLIN DERIVATIVE; SERUM ALBUMIN;

ARTICLE; ENDOTHELIUM CELL; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; GLYCATION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; MICROANGIOGRAPHY; MICROVASCULARIZATION; OLIGONUCLEOTIDE PROBE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNTHESIS; THROMBOGENESIS;

CYCLIC AMP; DNA, ANTISENSE; ENDOTHELIUM, VASCULAR; EPOPROSTENOL; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MICROCIRCULATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SERUM ALBUMIN, BOVINE; SKIN; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR;

EID: 0031773362     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051089     Document Type: Article

References (44)

1. Kannel WB, McGee DL (1979) Diabetes and cardiovascular disease: the Framingham study. JAMA 241: 2035-2038
2. L'Esperance FA, James WA, Judson PH (1990) The eye and diabetes mellitus. In: Lifkin H, Porte D (eds) Ellenberg and Rifkin's Diabetes Mellitus, Theory and Practice, Elsevier, New York, pp 661-683
3. Friedman EA (1990) Diabetic renal disease. In: Lifkin H, Porte D (eds) Ellenberg and Rifkin's Diabetes Mellitus, Theory and Practice, Elsevier, New York, pp 684-709
4. Egbert KO, Chiên TT, Adriana R, Fedor B (1984) Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 64: 907-913
5. Dawson S, Henney A (1992) The status of PAI-1 as a risk factor for arterial and thrombotic disease: A review. Atherosclerosis 95: 105-117
6. Páramo JA, Alfaro MJ, Rocha E (1985) Postoperative changes in the plasmatic levels of tissue-type plasminogen activator and its fast-acting inhibitor-relationship to deep vein thrombosis and influence of prophylaxis. Thrombosis and Hemostasis 54: 713-716
7. Páramo JA, Colucci M, Collen D (1985) Plasminogen activator inhibitor in the blood of patients with coronary artery disease. BMJ 291: 573-574
8. Hamsten A, Faire U, Walldius G, et al. (1987) Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 2: 3-8
9. Small M, Kluft C, MacCuish AC, Lowe GDO (1989) Tissue plasminogen activator inhibition in diabetes mellitus. Diabetes Care 12: 655-658
10. Auwerx J, Bouillon R, Collen D, Geboers J (1989) Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Atherosclerosis 8: 68-72
11. Brownlee M, Cerami A (1981) The biochemistry of the complications of diabetes mellitus. Annu Rev Biochem 50: 385-432
12. Brownlee M, Cerami A, Vlassara H (1988) Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318: 1315-1321
13. Vlassara H (1990) Chronic diabetic complications and tissue glycosylation. Diabetes Care 13 [Suppl.4]: 1180-1185
14. Yamagishi S, Kobayashi K, Yamamoto H (1993) Vascular pericytes not only regulate growth, but also preserve prostacyclin-producing ability and protect against lipid peroxide-induced injury of co-cultured endothelial cells. Biochem Biophys Res Commun 190: 418-425
15. 2, and prostacyclin. Pharmacol Rev 30: 293-331
16. Kuwabara T, Kogan DG (1960) Studies on the retinal vascular pattern. I. Normal Architecture. Arch Ophthalmol 64: 904-911
17. Yamagishi S, Hsu CC, Kobayashi K, Yamamoto H (1993) Endothelin 1 mediates endothelial cell-dependent proliferation of vascular pericytes. Biochem Biophys Res Commun 191: 840-846
18. Yamagishi S, Hsu CC, Taniguchi M et al. (1995) Receptor-mediated toxicity to pericytes of advanced glycosylation end products: A possible mechanism of pericyte loss in diabetic microangiopathy. Biochem Biophys Res Commun 213: 681-687
19. Yamagishi S, Yonekura H, Yamamoto Y et al. (1997) Advanced glycation endproducts-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J Biol Chem 272: 8723-8730
20. Bradford M (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principal of protein-dye binding. Anal Biochem 72: 248-254
21. Nomura M, Yamagishi S, Harada S et al. (1995) Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes. J Biol Chem 270: 28316-28324
22. Loskutoff D, Linders M, Keijer J, Veerman H, Van Heerikhuizen H, Pannekoek H (1987) Structure of the human plasminogen activator inhibitor 1 gene: Nonrandom distribution of introns. Biochemistry 26: 3763-3768
23. Riccio A, Grimaldi G, Verde P, Sebastio G, Boast S, Blasi F (1985) The human urokinase-plasminogen activator gene and its promotor. Nucleic Acids Res 13: 2759-2771
24. Itagaki Y, Yasuda H, Morinaga T, Mitsuda S, Higashio K (1991) Purification and characterization of tissue plasminogen activator secreted by human embryonic lung diploid fibroblasts, IMR-90 cells. Agric Biol Chem 55: 1225-1232
25. Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda R, Yamamoto H (1994) Vascular aldosterone: Biosynthesis and link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 269: 24316-24320
26. Pandolfi A, Iacoviello L, Capani F, Vitacolonna E, Donati MB, Consoli A (1996) Glucose and insulin independently reduce the fibrinolytic potential of human vascular smooth muscle cells in culture. Diabetologia 39: 1425-1431
27. Etingin OR, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL (1991) Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. J Biol Chem 266: 2459-2465
28. Yamagishi S, Yamamoto Y, Harada S, Hsu CC, Yamamoto H (1996) Advanced glycosylation end products stimulate the growth but inhibit the prostacyclin-producing ability of endothelial cells through interactions with their receptors. FEBS Lett 384: 103-106
29. Kaji M, Yonemura Y, Harada S, Liu X, Terada I, Yamamoto H (1996) Participation of c-met in the progression of human gastric cancers: anti-c-met oligonucleotides inhibit proliferation or invasiveness of gastric cancer cells. Cancer Gene Ther 3: 393-404
30. Santell L, Levin EG (1988) Cyclic AMP potentiates phorbol ester stimulation of tissue plasminogen activator release and inhibits secretion of plasminogen activator inhibitor-1 from human endothelial cells. J Biol Chem 263: 16802-16808
31. Whorton AR, Montgomery ME, Kent RS (1985) Effect of hydrogen peroxide on prostaglandin production and cellular integrity in cultured porcine aortic endothelial cells. J Clin Invest 76: 295-302
32. 2 balance in the diabetic rat. Diabetes 31: 947-951
33. Yan SD, Schmidt AM, Anderson GM et al. (1994) Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269: 9889-9897
34. Martina V, Bruno G A, Pannocchia A et al. (1996) PAI-1 reduction after treatment with glutathione in NIDDM. Fibrinolysis 10 [Supp 2]: 63-65
35. Geiger M, Binder BR (1984) Plasminogen activation in diabetes mellitus. J Biol Chem 259: 2976-2981
36. Geiger M, Binder BR (1986) Nonenzymatic glycosylation as a contributing factor to defective fibrinolysis in diabetes mellitus. Haemostasis 16: 439-446
37. Makita Z, Vlassara H, Cerami A, Bucala R (1992) Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 267: 5133-5138
38. Dollery CT, Friedman LA, Hensby CN et al. (1979) Circulating prostacyclin may be reduced in diabetes. Lancet 2: 1365
39. Maiello M, Boeri D, Podesta F et al. (1992) Increased expression of tissue plasminogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose. Diabetes 41: 1009-1015
40. Hopkins NK, Gorman RR (1981) Regulation of endothelial cell cyclic nucleotide metabolism by prostacyclin. J Clin Invest 67: 540-546
41. Kooistra T, Bosma PJ, Toet K et al. (1991) Role of protein kinase C and cyclic adenosine monophosphate in the regulation of tissue-type plasminogen activator, plasminogen activator inhibitor-1, and platelet-derived growth factor mRNA levels in human endothelial cells. Arteriosclerosis and Thrombosis 11: 1042-1052
42. Wautier JL, Wautier MP, Schmidt AM et al. (1994) Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: A link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci USA 91: 7742-7746
43. Descheemaeker KA, Wyns S, Nelles L, Auwerx J, Ny T, Collen D (1992) Interaction of AP-1-, AP-2-, and SP 1-like proteins with two distinct sites in the upstream regulatory region of te plasminogen activator inhibitor-1 gene mediates the phorbol 12-myristate 13-acetate response. J Biol Chem 267: 15086-15091
44. Ollivier V, Parry GCN, Cobb RR, De Prost D, Macjman N (1996) Elevated cyclic AMP inhibits NF-κB-mediated transcription in human monocytic cells and endothelial cells. J Biol Chem 271: 20828-20835